Delivered through our partner network · enterprise logos placed with permission
Life sciences AI consulting helps pharma, biotech, and medical device organizations strengthen data readiness, improve regulatory alignment, and accelerate AI adoption across clinical, operational, and commercial workflows.
The drug discovery process is still time-consuming, expensive and information-rich. Teams frequently face disjointed data, broken workflows and inefficient analytical workflows that slow down time to market. According to McKinsey AI in life sciences has the potential to add $60 billion to $110 billion in value to pharmaceutical and medical products each year. Life sciences AI consulting assists in prioritizing high-value AI drug discovery use cases and enhancing the development efficiency.
Large amounts of structured and unstructured data are created and collected from clinical trials, spanning sites, systems and patient populations. Such complexity makes it hard to get timely insights and early indicators of performance risks. A research shows that almost 80% of clinical trial data goes unused in development. Improved clinical trial AI strategy leads to better data visibility, faster decision-making, and better quality of trial execution.
Validated models, data lineage, and documentation are needed for regulatory submissions. The weaker the AI validation controls, the greater the risk of submission and the longer the review cycles. The FDA reiterates the importance of transparency, validation, and lifecycle controls for AI-powered medical products. Effective regulatory compliance AI systems minimize approval friction and enhance audit readiness.
Life sciences teams are generally scientific deep, but lack in-house expertise in AI governance, validation frameworks, and responsible deployment. This limitation hinders adoption and risk exposure. PwC discovered that 60% of executives feel that responsible AI boosts ROI and efficiency. Life sciences AI consulting can support the development of real-world governance and compliance agility prior to scale.
While postmarket surveillance provides important safety, usage, and real-world evidence data, many organizations have a challenge with using this data to provide actionable insight. The FDA's Sentinel Initiative tracks information from over 70 million patients to enhance the detection of drug safety issues. AI in pharmacovigilance aids in detecting new signals faster and enhances existing follow-up during the product lifecycle.
General-purpose AI vendors may be knowledgeable about technology, but not clinical trials, regulatory pathways, drug safety, and life sciences operating environments. This makes for a poor fit and slow implementation. One of the consistent findings of McKinsey is that deployment capability in the domain is a key factor in the results of AI. In the life sciences sector, AI consulting helps align technical implementations with reality.
Outline priorities for research, clinical and regulatory and commercial functions. Define priority use cases, evaluate organizational preparedness, and draw out use case plans for phased adoption. A roadmap provides a framework for investment decisions, mitigates execution risk, and ensures life sciences digital transformation is aligned with business outcomes.
In-House
01/ AI Strategy and Roadmap
Streamline and automate clinical trial data transfer between sites, patient records and study systems. Simplify data preparation, enhance trial visibility and speed up insight generation. By automating manual review cycles, ensuring high data quality, and aiding faster decision making within complex development programs, Clinical trial AI ensures a more efficient process.
In-House
02/ Clinical Trial AI
Create governance measures, validation criteria, and documentation that can be tracked for AI-assisted workflows. Enhance regulatory preparedness for FDA, HIPAA and quality. Regulatory compliance AI minimises submission risk, prepares for audits and facilitates trusted deployment in life sciences environments.
In-House
03/ Regulatory Compliance
Collect, process and investigate machine learning signals, adverse event reports and postmarket data. Identify and prioritize signaling risks sooner and improve drug safety monitoring systems. AI in pharmacovigilance aids in quicker response and uniform lifecycle management.
In-House
04/AI in Pharmacovigilance
Handle large amounts of genomic data to enhance pattern recognition, research interpretation, and biomarker discovery. Use sophisticated analytics to speed insight generation across precision medicine and R&D programs. Genomic analytics AI helps scientists make better decisions and speed up the analysis process.
In-House
05/Life Sciences Supply
Improve forecasting, inventory visibility and operational coordination within manufacturing and supply chains. Improve Data-driven Planning, Early Identification of Bottlenecks and Decrease Disruption Risk. AI-driven supply chain management increases speed to market, supports continuity, and enhances resilience.
In-House
06/ Life Sciences Supply
Life sciences AI consulting helps organizations strengthen data readiness, regulatory alignment, and operational foundations before scale. Build practical pathways for faster innovation, better decision-making, and measurable outcomes across clinical and commercial functions.
Decide on promising therapeutic targets at an earlier stage by analysing large biological datasets, genomic signals and research literature. By reducing discovery timelines, enhancing candidate prioritization, and directing research efforts toward more likely development paths, AI contributes to the effective use of resources in research teams. According to the Tufts Center for the Study of Drug Development, bringing a new medicine to market can take more than 10 years, which makes earlier target identification critical for reducing downstream delays.
Apply clinical and historical patient information to enhance protocol design and cohort selection, and to minimize enrollment friction. Improved trial design enhances trial execution quality, increases recruitment speed, and assists in the reliability of study findings. Clinical trial enrollment delays affect more than 80% of clinical trials, making patient cohort selection a major operational bottleneck.
Structure evidence of validation, traceable documentation, and model governance controls prior to submission. A well-prepared FDA is better equipped to support Software as a Medical Device programs and minimise compliance gaps and delays.
Identify useful trends sooner from real-world data, post-market data, and safety reports. The increased signal speed enhances pharmacovigilance, visibility of the product lifecycle and enables better clinical decisions.
Automate the documentation process from study summary to submission content and regulatory authoring. Consistency, less manual effort, and more efficient management of increasing documentation complexity are all advantages of structured content generation.
Track production quality, inventory flow and production bottlenecks in manufacturing processes. AI-driven visibility enhances forecast accuracy, minimises disruption risks and bolsters supply chain resiliency in complex life sciences operations.
Connect with a curated network of life sciences AI consultants who span the pharma, biotech, medical devices, clinical operations and regulatory landscapes. There is greater certainty of delivery and less risk of execution when there is a better fit.
Match clinical, genomics, digital health, or medical devices consulting skills to actual operational needs in drug discovery and clinical trials, pharmacovigilance, genomics, digital health, or medical devices. Sub-vertical alignment boosts relevance, speeds up discovery and fine-tunes implementation priorities.
Validate AI planning with expectations, audit traceability and FDA-compliant documentation structures. Preparing early eliminates approval friction and builds confidence in regulated deployment environments.
Quickly kick off projects with a structured discovery process, clear scoping and focused capability matching. By engaging more quickly, organizations can speed up internal evaluation and make the transition from planning to action with greater momentum.
Establish baseline expectations for healthcare privacy, data governance, and enterprise security. Firm groundwork in compliance minimizes operational danger and ensures responsible adoption of AI in sensitive clinical and commercial settings.
Work with seasoned life sciences professionals who are familiar with clinical workflows, regulatory pathways, product lifecycle complexity and data-driven transformation. Senior experience delivers better decision-making and faster time-to-value for business outcomes.
Every quote reflects a real engagement. No stock photos, no composite personas — just clinical leaders who moved from stuck to shipped.
"Cognixis didn't sell us a tool — they fixed our compliance architecture first. In eight weeks we went from three stalled clinical AI pilots to a governance framework our board and clinical risk committee actually signed off on. Six months later our predictive readmission model is reducing 30-day readmissions by 23% across two hospital sites."
"We'd failed two previous EHR-AI integration attempts before Cognixis. They diagnosed the data governance gap in the first week and matched us with a partner who actually understood FHIR. We shipped in 14 weeks."
"Their governance framework got us through TGA SaMD classification and NSQHS review without a single compliance finding. That outcome alone justified the entire engagement cost within the first quarter."
"As a GP practice we assumed enterprise AI wasn't accessible at our scale. Cognixis scoped a clinical documentation automation pilot that paid for itself in 9 weeks — and we didn't need a full IT team to run it."
"What I valued most was the no-vendor-bias stance. Every recommendation was defensible on clinical grounds, not tied to a commercial relationship. That's genuinely rare in healthcare AI consulting."
Life sciences AI consulting empowers pharma, biotech, and medical device businesses to translate intricate data, regulatory mandates, and operational obstacles into actionable AI strategies, driving growth, compliance, and impactful business results.
Long-form POVs, governance frameworks, and field benchmarks on what actually works in production healthcare AI. Hover to pause.
The structure, artifacts, and review cadence that satisfies TGA SaMD requirements without slowing deployment velocity.
How to connect AI systems to your EHR without creating data silos, compliance gaps, or HL7 translation nightmares.
The model design, data pipeline, and governance framework behind a validated predictive risk deployment at a regional hospital network.
A practitioner's reference for navigating overlapping privacy obligations when deploying AI across clinical data environments.
The five most common validation gaps that surface during post-go-live TGA audits — and how to close them before deployment.
Change management, privacy disclosure, and workflow design patterns from practices that achieved 70%+ documentation time reduction.
Why 60% of CDSS deployments are bypassed within 6 months — and the alert design and workflow integration principles that reverse it.
How one imaging network deployed AI-assisted triage across 8 sites while passing ARTG review and maintaining radiologist confidence.
The structure, artifacts, and review cadence that satisfies TGA SaMD requirements without slowing deployment velocity.
How to connect AI systems to your EHR without creating data silos, compliance gaps, or HL7 translation nightmares.
The model design, data pipeline, and governance framework behind a validated predictive risk deployment at a regional hospital network.
A practitioner's reference for navigating overlapping privacy obligations when deploying AI across clinical data environments.
The five most common validation gaps that surface during post-go-live TGA audits — and how to close them before deployment.
Change management, privacy disclosure, and workflow design patterns from practices that achieved 70%+ documentation time reduction.
Why 60% of CDSS deployments are bypassed within 6 months — and the alert design and workflow integration principles that reverse it.
How one imaging network deployed AI-assisted triage across 8 sites while passing ARTG review and maintaining radiologist confidence.
For drug and biotech companies, medical device firms, and digital health companies, life sciences AI consulting services can identify where AI can deliver science and operational impact. It usually includes AI Strategy, Data Readiness, Governance Planning, Clinical Trial Analytics, Pharmacovigilance, Genomic Analytics, Real-World Evidence Analysis, Regulatory Readiness, Manufacturing Optimization, and Supply Chain Decision Support. The aim is to coordinate AI efforts with business needs, scientific processes, and legal regulations before significant investments are made. The intention is to harmonize AI activities with business needs, scientific workflows, and compliance requirements prior to the start of large-scale investment.
AI in life sciences plays a role in a number of aspects of the product lifecycle. During drug discovery, machine learning can be applied to target identification, molecular pattern analysis, and prioritizing candidate compounds at an early stage of the discovery process. AI enhances patient selection, protocol development, patient recruitment prediction, and quality control in clinical trials. AI is also being used in pharmacovigilance, postmarket surveillance, regulatory authoring, genomic analytics, and real-world evidence analysis to enhance the speed of decision making, data quality, and efficiency.
A CTO should possess deep domain knowledge of life sciences and technical execution skills. A good partner for consulting should be familiar with clinical development, regulatory routes, validation needs, data governance and enterprise operating environments. Understanding the experience of integrating AI into scientific workflows, compliance requirements, and quantifiable business goals is also essential to ensure that the implementation aligns with the organization's operational requirements and is scalable for the future.
Cognixis begins with discovery to gain insight into business priorities, operational maturity, scientific workflows, regulatory requirements and desired outcomes. This evaluation will then allow Cognixis to match organisations to specialists that are experienced in the sub-vertical relevant to the pharma, biotech, medical devices, genomics, pharmacovigilance, clinical operations, etc. The structured matching process enhances fit, minimizes evaluation time, and boosts implementation confidence.
The duration of most life sciences AI consulting projects is typically within a few weeks, but can be longer depending on the size of the organization, availability of stakeholders, access to data, and the complexity of the problem to be solved. Readiness or strategy engagements are usually smaller and faster in pace, while enterprise engagements with multiple clinical, regulatory and operational functions tend to be more in-depth and will take longer before action can take place.
Regulatory landscape and its impact on clinical development, product lifecycle management, and data governance should be understood by life sciences AI consulting partners. This generally means FDA standards for validation, traceability, and lifecycle controls, as well as HIPAA standards for the protection of PII. Also, depending on the operating markets, partners might require experience in GDPR, pharmacovigilance requirements, postmarket surveillance needs, and Software as a Medical Device standards to ensure a compliant and responsible approach to AI deployment.